Octapharma: Hemophilia A trials

The registry lists 15 Hemophilia A studies with Octapharma as lead sponsor. 3 are open to participants now and 12 have results posted.

Phase 1 1Phase 2 2Phase 3 8Phase 4 2No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for SurgeryRecruitingNCT05936580Phase 4
• Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis StudyRecruitingNCT05935358Phase 4
• Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A PatientsRecruitingNCT03695978
• Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia ATerminatedNCT04046848Phase 1/2Results posted
• Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients With Severe Haemophilia ACompletedNCT03376516Phase 3Results posted
• Immune Tolerance Induction in Haemophilia A Patients Using Wilate or NuwiqTerminatedNCT03344003Results posted
• Non-interventional Post-authorisation Study to Document the Immunogenicity, Safety, and Efficacy of NUWIQCompletedNCT02962765Results posted
• Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia ACompletedNCT02954575Phase 3Results posted
• Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia ACompletedNCT02256917Phase 3Results posted
• Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIIICompletedNCT01992549Phase 3Results posted
• Assess the Safety and Efficacy of Individually Tailored Prophylaxis With Human-cl rhFVIII in Patients With Severe Haemophilia ACompletedNCT01863758Phase 3Results posted
• Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated PatientsCompletedNCT01712438Phase 3Results posted
• Study to Investigate the Long-term Efficacy and Safety of Human-cl rhFVIII in Previously Treated Patients (PTPs)CompletedNCT01341912Phase 3Results posted
• Efficacy and Safety Study of Human-cl rhFVIII in PTPs With Severe Hemophilia ACompletedNCT01125813Phase 3Results posted
• Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia ACompletedNCT00989196Phase 2Results posted